Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioMarin (NASDAQ:BMRN) and Penumbra Inc (NYSE:PEN).
BioMarin (BMRN)
Citigroup analyst Robyn Karnauskas maintained a Buy rating on BioMarin today and set a price target of $120. The company’s shares closed yesterday at $103.32, close to its 52-week high of $106.20.
According to TipRanks.com, Karnauskas is a 4-star analyst with an average return of 4.5% and a 52.3% success rate. Karnauskas covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Myovant Sciences, and Biogen Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioMarin with a $117.77 average price target, implying a 14.0% upside from current levels. In a report issued on July 30, Canaccord Genuity also maintained a Buy rating on the stock with a $113 price target.
.
See today’s analyst top recommended stocks >>
Penumbra Inc (PEN)
In a report released today, Joanne Wuensch from BMO Capital maintained a Hold rating on Penumbra Inc, with a price target of $150. The company’s shares closed yesterday at $124.65.
According to TipRanks.com, Wuensch is a 5-star analyst with an average return of 12.4% and a 72.7% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Baxter International, and Edwards Lifesciences.
Currently, the analyst consensus on Penumbra Inc is a Strong Buy with an average price target of $163.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
